A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHN’S DISEASE

BACKGROUND: Tolerance to therapy is critical for pts to receive the maximal treatment benefit. In Phase 3 clinical trials for ustekinumab (UST) for moderate to severe Crohn’s disease (CD), UNITI-1 enrolled anti-TNF failures and UNITI-2 enrolled conventional therapy failures. In UNITI-1, 36.4% had pr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Can Assoc Gastroenterol
Main Authors: Loftus, E V, Sattin, B D, Jacobstein, D, Gasink, C, Sloan, S, Feagan, B G, Colombel, J F
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Paper Sessions
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508225/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.102
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki